Northwire Canada EditionFriday, July 24, 2026
Sign inSubscribe
Northwire
⌕
AVX 0.005 −nan% AII 19.91 −1.0% GWM 0.480 +0.0% GEN 0.065 +0.0% NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0% AVX 0.005 −nan% AII 19.91 −1.0% GWM 0.480 +0.0% GEN 0.065 +0.0% NIO 0.135 −3.6% III 7.22 −2.8% NCAU 0.295 −3.3% NEV 0.040 +0.0% ITR 3.00 −1.6% ALDE 2.79 −0.7% TECK 84.18 +4.4% FVI 11.83 −2.2% SUM 1.31 −1.5% RSMX 0.115 +4.5% STW 0.105 +5.0% PAT 0.250 +0.0%
Other

LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES

By The Northwire Desk — AI Analysis Aug 04, 2025 · 16:45 LSL · 0.425 LSL Pharma Group Inc.
LSL · Price

Executive Summary

  • LSL Pharma Group completed the early redemption and cancellation of all its 11.0% Unsecured Convertible Debentures, which were originally scheduled to mature on October 31, 2028.
  • The company paid debenture holders an aggregate total of $3,505,098.08, covering the principal amount, an early repayment premium, and accrued interest.
  • The debentures (symbol: LSL.DB) were delisted from the TSX Venture Exchange and ceased trading on August 1, 2025.

Key Details

  • Transaction: Early redemption and cancellation of all issued and outstanding 11.0% Unsecured Convertible Debentures.
  • Original Maturity Date: October 31, 2028.
  • Total Payment to Holders: $3,505,098.08.
  • Principal Amount Repaid: $3,288,000.
  • Payment Components: The aggregate amount included the principal, the early repayment premium as per the trust indenture dated November 1, 2023, and all accrued and unpaid interest up to the Redemption Date.
  • Delisting Status: Debentures delisted from the TSX Venture Exchange under symbol LSL.DB; ceased trading on August 1, 2025.
  • Trustee: TSX Trust Company.

Notable Quotes

  • No direct quotes from management were included in the release text provided.
Read the original news release →

More from LSL Pharma Group Inc.

May 28, 2026 · 07:00

Revenue Growth Masks Profitability Concerns as Operational Scaling Continues

Production / Operations May 25, 2026 · 12:00

Revenue Surge Masks Cash Burn Risk as Integration Costs Mount

Earnings May 25, 2026 · 07:00

Revenue Surge Masks Integration Costs as LSL Pharma Tests Regulatory Resilience

Earnings Apr 30, 2026 · 07:00

LSL Pharma Delivers Revenue Surge But Profitability Erosion Signals Costly Growth Phase

Earnings Apr 09, 2026 · 07:00

Juno OTC secures Loratadine RDT partnership, expanding Canadian OTC pipeline

M&A / Property Jan 28, 2026 · 16:07

LSL obtains FDA certification for ophthalmic ointments

Production / Operations